

Michael Lassmann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3619536/publications.pdf>

Version: 2024-02-01

161
papers

9,787
citations

34105

52
h-index

39675

94
g-index

183
all docs

183
docs citations

183
times ranked

6635
citing authors

#	ARTICLE	IF	CITATIONS
1	Toward a Patient-Specific Traceable Quantification of SPECT/CT-Based Radiopharmaceutical Distributions. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1108-1116.	5.0	1
2	The effect of modern PET technology and techniques on the EANM paediatric dosage card. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1964-1969.	6.4	7
3	Quantification of the volume fraction of fat, water and bone mineral in spongiosa for red marrow dosimetry in molecular radiotherapy by using a dual-energy (SPECT/CT). <i>Zeitschrift Fur Medizinische Physik</i> , 2022, 32, 428-437.	1.5	1
4	Modelling SPECT auto-contouring acquisitions for ^{177}Lu & ^{131}I molecular radiotherapy using new developments in Geant4/GATE. <i>Physica Medica</i> , 2022, 96, 101-113.	0.7	2
5	mRNA and small RNA gene expression changes in peripheral blood to detect internal Ra-223 exposure. <i>International Journal of Radiation Biology</i> , 2022, 98, 900-912.	1.8	2
6	GATE/Geant4-based dosimetry for ex vivo in solution irradiation of blood with radionuclides. <i>Zeitschrift Fur Medizinische Physik</i> , 2022, , .	1.5	0
7	Is a single late SPECT/CT based kidney ^{177}Lu -dosimetry superior to hybrid dosimetry with sequential multiple time-point whole-body planar scans in combination with an early SPECT/CT?. <i>Physica Medica</i> , 2022, 100, 39-50.	0.7	0
8	Repair of β -particle-induced DNA damage in peripheral blood mononuclear cells after internal ex vivo irradiation with ^{223}Ra . <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 3981-3988.	6.4	3
9	EANM position paper on article 56 of the Council Directive 2013/59/Euratom (basic safety standards) for nuclear medicine therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 67-72.	6.4	62
10	Developing and Implementing an Imaging Optimization Study in Pediatric Nuclear Medicine: Experience and Recommendations from an IAEA-Coordinated Research Project. <i>Journal of Nuclear Medicine</i> , 2021, 62, 570-576.	5.0	4
11	Developing and implementing a multi-modality imaging optimization study in paediatric radiology: Experience and recommendations from an IAEA coordinated research project. <i>Physica Medica</i> , 2021, 82, 255-265.	0.7	2
12	EANM position paper on the role of radiobiology in nuclear medicine. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3365-3377.	6.4	23
13	A multicentre and multi-national evaluation of the accuracy of quantitative Lu-177 SPECT/CT imaging performed within the MRTDosimetry project. <i>EJNMMI Physics</i> , 2021, 8, 55.	2.7	34
14	Dosimetry for Radiopharmaceutical Therapy: The European Perspective. <i>Journal of Nuclear Medicine</i> , 2021, 62, 73S-79S.	5.0	7
15	Paediatric nuclear medicine practice: an international survey by the IAEA. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1552-1563.	6.4	12
16	What You See Is Not What You Get: On the Accuracy of Voxel-Based Dosimetry in Molecular Radiotherapy. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1178-1186.	5.0	25
17	DNA Damage in Blood Leukocytes of Prostate Cancer Patients Undergoing PET/CT Examinations with ^{68}Ga -PSMA I&T. <i>Cancers</i> , 2020, 12, 388.	3.7	9
18	Setting up a quantitative SPECT imaging network for a European multi-centre dosimetry study of radioiodine treatment for thyroid cancer as part of the MEDIRAD project. <i>EJNMMI Physics</i> , 2020, 7, 61.	2.7	23

#	ARTICLE	IF	CITATIONS
19	EANM Dosimetry Committee series on standard operational procedures for internal dosimetry for 131I mIBG treatment of neuroendocrine tumours. EJNMMI Physics, 2020, 7, 15.	2.7	44
20	Will SPECT/CT Cameras Soon Be Able to Display Absorbed Doses? Dosimetry from Single-Activity-Concentration Measurements. Journal of Nuclear Medicine, 2020, 61, 1028-1029.	5.0	9
21	Characterization of Noise and Resolution for Quantitative ¹⁷⁷ Lu SPECT/CT with xSPECT Quant. Journal of Nuclear Medicine, 2019, 60, 50-59.	5.0	51
22	EANM procedure guidelines for radionuclide therapy with ¹⁷⁷ Lu-labelled PSMA-ligands (¹⁷⁷ Lu-PSMA-RLT). European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2536-2544.	6.4	265
23	Quantification of the trabecular bone volume fraction for bone marrow dosimetry in molecular radiotherapy by using a dual-energy (SPECT/CT). Physics in Medicine and Biology, 2019, 64, 205014.	3.0	2
24	ICRP Publication 140: Radiological Protection in Therapy with Radiopharmaceuticals. Annals of the ICRP, 2019, 48, 5-95.	3.8	45
25	DNA damage in blood leucocytes of prostate cancer patients during therapy with ¹⁷⁷ Lu-PSMA. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1723-1732.	6.4	13
26	In Vivo Biokinetics of ¹⁷⁷ Lu-OPS201 in Mice and Pigs as a Model for Predicting Human Dosimetry. Contrast Media and Molecular Imaging, 2019, 2019, 1-7.	0.8	11
27	Nanostructure of Clustered DNA Damage in Leukocytes after In-Solution Irradiation with the Alpha Emitter Ra-223. Cancers, 2019, 11, 1877.	3.7	27
28	Radioiodine dosimetry in advanced thyroid cancer. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2019, 63, 227-228.	0.7	1
29	Targeted alpha-particle therapy: imaging, dosimetry, and radiation protection. Annals of the ICRP, 2018, 47, 187-195.	3.8	24
30	DNA damage in leukocytes after internal ex-vivo irradiation of blood with the Î±-emitter Ra-223. Scientific Reports, 2018, 8, 2286.	3.3	29
31	Microscale radiosynthesis, preclinical imaging and dosimetry study of [18F]AMBF3-TATE: A potential PET tracer for clinical imaging of somatostatin receptors. Nuclear Medicine and Biology, 2018, 61, 36-44.	0.6	26
32	Dose Mapping After Endoradiotherapy with ¹⁷⁷ Lu-DOTATATE/DOTATOC by a Single Measurement After 4 Days. Journal of Nuclear Medicine, 2018, 59, 75-81.	5.0	125
33	Safety, Biodistribution, and Radiation Dosimetry of ⁶⁸ Ga-OPS202 in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase I Imaging Study. Journal of Nuclear Medicine, 2018, 59, 909-914.	5.0	65
34	From fixed activities to personalized treatments in radionuclide therapy: lost in translation?. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 152-154.	6.4	34
35	Quantification of fat fraction in lumbar vertebrae: correlation with age and implications for bone marrow dosimetry in molecular radiotherapy. Physics in Medicine and Biology, 2018, 63, 025029.	3.0	19
36	Optimizing Image Quantification for ¹⁷⁷ Lu SPECT/CT Based on a 3D Printed 2-Compartment Kidney Phantom. Journal of Nuclear Medicine, 2018, 59, 616-624.	5.0	38

#	ARTICLE	IF	CITATIONS
37	Inter-comparison of quantitative imaging of lutetium-177 (177Lu) in European hospitals. EJNMMI Physics, 2018, 5, 17.	2.7	19
38	Correlation of the absorbed dose to the blood and DNA damage in leukocytes after internal ex-vivo irradiation of blood samples with Ra-224. EJNMMI Research, 2018, 8, 77.	2.5	14
39	I-131 as adjuvant treatment for differentiated thyroid carcinoma may cause an increase in the incidence of secondary haematological malignancies: an "inconvenient" truth?. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2247-2249.	6.4	9
40	The Relevance of Dosimetry in Precision Medicine. Journal of Nuclear Medicine, 2018, 59, 1494-1499.	5.0	39
41	Biokinetics, dosimetry, and radiation risk in infants after 99mTc-MAG3 scans. EJNMMI Research, 2018, 8, 10.	2.5	6
42	Nuklearmedizinische Therapie. , 2018, , 377-386.		0
43	Dosimetric Approaches: Current Concepts. , 2018, , 137-145.		1
44	Multi-centre evaluation of accuracy and reproducibility of planar and SPECT image quantification: An IAEA phantom study. Zeitschrift Fur Medizinische Physik, 2017, 27, 98-112.	1.5	35
45	¹³¹ I activity quantification of gamma camera planar images. Physics in Medicine and Biology, 2017, 62, 909-926.	3.0	7
46	Internal Dosimetry: Principles and Applications to NET. , 2017, , 201-217.		1
47	The "reset button" revisited: why high activity ¹³¹ I therapy of advanced differentiated thyroid cancer after dosimetry is advantageous for patients. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 915-917.	6.4	16
48	Comparison of Empiric Versus Dosimetry-Guided Radioiodine Therapy: The Devil Is in the Details. Journal of Nuclear Medicine, 2017, 58, 862-862.	5.0	8
49	The conflict between treatment optimization and registration of radiopharmaceuticals with fixed activity posology in oncological nuclear medicine therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1783-1786.	6.4	48
50	The IAEA Radiotracer Biodistribution Template "A community resource for supporting the standardization and reporting of radionuclide pre-dosimetry data. Physica Medica, 2017, 44, 83-85.	0.7	5
51	Individualized Dosimetry for Theranostics: Necessary, Nice to Have, or Counterproductive?. Journal of Nuclear Medicine, 2017, 58, 97S-103S.	5.0	83
52	Human Biodistribution and Radiation Dosimetry of ¹⁸ F-Clofarabine, a PET Probe Targeting the Deoxyribonucleoside Salvage Pathway. Journal of Nuclear Medicine, 2017, 58, 374-378.	5.0	17
53	[¹⁷⁷ Lu]pentixather: Comprehensive Preclinical Characterization of a First CXCR4-directed Endoradiotherapeutic Agent. Theranostics, 2017, 7, 2350-2362.	10.0	84
54	Absorbed dose estimates from a single measurement one to three days after the administration of ¹⁷⁷ Lu-DOTATATE/-TOC. Nuklearmedizin - NuclearMedicine, 2017, 56, 219-224.	0.7	11

#	ARTICLE	IF	CITATIONS
55	Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors - a Triple Tracer Comparative Approach. <i>Theranostics</i> , 2017, 7, 1489-1498.	10.0	82
56	68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CT. <i>Clinical Nuclear Medicine</i> , 2016, 41, 515-521.	1.3	165
57	Standardization of Administered Activities in Pediatric Nuclear Medicine: A Report of the First Nuclear Medicine Global Initiative Project, Part 2â€”Current Standards and the Path Toward Global Standardization. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1148-1157.	5.0	26
58	Design and Fabrication of Kidney Phantoms for Internal Radiation Dosimetry Using 3D Printing Technology. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1998-2005.	5.0	40
59	Synthesis and preclinical evaluation of an Al18F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligand. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 2122-2130.	6.4	42
60	177Lu-OPS201 targeting somatostatin receptors: in vivo biodistribution and dosimetry in a pig model. <i>EJNMMI Research</i> , 2016, 6, 50.	2.5	15
61	Standardization of pediatric nuclear medicine administered radiopharmaceutical activities: the SNMMI/EANM Joint Working Group. <i>Clinical and Translational Imaging</i> , 2016, 4, 203-209.	2.1	1
62	Standardization of administered activities in paediatric nuclear medicine: the EANM perspective. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 2275-2278.	6.4	4
63	DNA Damage in Peripheral Blood Lymphocytes of Thyroid Cancer Patients After Radioiodine Therapy. <i>Journal of Nuclear Medicine</i> , 2016, 57, 173-179.	5.0	49
64	Recommended administered activities for 68Ga-labelled peptides in paediatric nuclear medicine. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 2036-2039.	6.4	10
65	Dose optimization in nuclear medicine. <i>Clinical and Translational Imaging</i> , 2016, 4, 3-4.	2.1	3
66	Dose optimization in pediatric nuclear medicine. <i>Clinical and Translational Imaging</i> , 2016, 4, 5-11.	2.1	3
67	First-in-Human Experience of CXCR4-Directed Endoradiotherapy with ¹⁷⁷ Lu- and ⁹⁰ Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease. <i>Journal of Nuclear Medicine</i> , 2016, 57, 248-251.	5.0	201
68	Dose optimization in nuclear medicine therapy of benign and malignant thyroid diseases. <i>Clinical and Translational Imaging</i> , 2016, 4, 31-40.	2.1	3
69	MIRD Pamphlet No. 26: Joint EANM/MIRD Guidelines for Quantitative ¹⁷⁷ Lu SPECT Applied for Dosimetry of Radiopharmaceutical Therapy. <i>Journal of Nuclear Medicine</i> , 2016, 57, 151-162.	5.0	235
70	Radiation Safety and Dosimetry. , 2016, , 103-111.		0
71	SPECT- and PET-Based Patient-Tailored Treatment in Neuroendocrine Tumors. <i>Clinical Nuclear Medicine</i> , 2015, 40, e271-e277.	1.3	9
72	Disclosing the CXCR4 Expression in Lymphoproliferative Diseases by Targeted Molecular Imaging. <i>Theranostics</i> , 2015, 5, 618-630.	10.0	162

#	ARTICLE	IF	CITATIONS
73	Current status and future perspectives of PSMA-targeted therapy in Europe: opportunity knocks. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1971-1975.	6.4	17
74	Differences in 3D dose distributions due to calculation method of voxel S-values and the influence of image blurring in SPECT. Physics in Medicine and Biology, 2015, 60, 1945-1964.	3.0	36
75	The absorbed dose to blood from blood-borne activity. Physics in Medicine and Biology, 2015, 60, 741-753.	3.0	4
76	Biodistribution and Radiation Dosimetry for the Chemokine Receptor CXCR4-Targeting Probe ⁶⁸ Ga-Pentixafor. Journal of Nuclear Medicine, 2015, 56, 410-416.	5.0	108
77	⁶⁸ Ga- and ¹⁷⁷ Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies. Journal of Nuclear Medicine, 2015, 56, 1169-1176.	5.0	432
78	Biodistribution and Radiation Dosimetry for a Probe Targeting Prostate-Specific Membrane Antigen for Imaging and Therapy. Journal of Nuclear Medicine, 2015, 56, 855-861.	5.0	122
79	A multicentre comparison of quantitative 90Y PET/CT for dosimetric purposes after radioembolization with resin microspheres. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1202-1222.	6.4	131
80	The NUKDOS software for treatment planning in molecular radiotherapy. Zeitschrift Fur Medizinische Physik, 2015, 25, 264-274.	1.5	41
81	Standardization of Administered Activities in Pediatric Nuclear Medicine: A Report of the First Nuclear Medicine Global Initiative Project, Part 1 – Statement of the Issue and a Review of Available Resources. Journal of Nuclear Medicine, 2015, 56, 646-651.	5.0	32
82	DNA damage in blood lymphocytes in patients after ¹⁷⁷ Lu peptide receptor radionuclide therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1739-1749.	6.4	38
83	EANM practice guidelines for lymphoscintigraphy and sentinel lymph node biopsy in melanoma. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1750-1766.	6.4	110
84	Calibration of the ³ H2AX DNA Double Strand Break Focus Assay for Internal Radiation Exposure of Blood Lymphocytes. PLoS ONE, 2015, 10, e0123174.	2.5	47
85	Radiation Dosimetry Aspects of ¹⁷⁷ Lu. Current Radiopharmaceuticals, 2015, 8, 139-144.	0.8	14
86	Influence of CT-based attenuation correction on dopamine transporter SPECT with [(123)I]FP-CIT. American Journal of Nuclear Medicine and Molecular Imaging, 2015, 5, 278-86.	1.0	6
87	Nicotinic Acetylcholine Receptor Density in Cognitively Intact Subjects at an Early Stage of Parkinson's Disease. Frontiers in Aging Neuroscience, 2014, 6, 213.	3.4	21
88	SNMMI and EANM Practice Guideline for Meckel Diverticulum Scintigraphy 2.0. Journal of Nuclear Medicine Technology, 2014, 42, 163-169.	0.8	51
89	Biting the magic bullet: celebrating a decade of the EANM Dosimetry Committee. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1-3.	6.4	9
90	Self-irradiation of the blood from selected nuclides in nuclear medicine. Physics in Medicine and Biology, 2014, 59, 1515-1531.	3.0	8

#	ARTICLE	IF	CITATIONS
91	The limit of detection in scintigraphic imaging with I-131 in patients with differentiated thyroid carcinoma. Physics in Medicine and Biology, 2014, 59, 2353-2368.	3.0	16
92	International Guidelines for Pediatric Radiopharmaceutical Administered Activities. Journal of Nuclear Medicine, 2014, 55, 869-870.	5.0	23
93	Paediatric radiopharmaceutical administration: harmonization of the 2007 EANM paediatric dosage card (version 1.5.2008) and the 2010 North American consensus guidelines. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1036-1041.	6.4	124
94	Pediatric Radiopharmaceutical Administration: Harmonization of the 2007 EANM Paediatric Dosage Card (Version 1.5.2008) and the 2010 North American Consensus guideline. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1636-1636.	6.4	61
95	The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1976-1988.	6.4	179
96	Pretreatment Dosimetry in HCC Radioembolization with 90Y Glass Microspheres Cannot Be Invalidated with a Bare Visual Evaluation of 99mTc-MAA Uptake of Colorectal Metastases Treated with Resin Microspheres. Journal of Nuclear Medicine, 2014, 55, 1215-1216.	5.0	16
97	18F-FDG PET/CT scans for children and adolescents. Lancet Oncology, The, 2014, 15, e243-e244.	10.7	2
98	Clinical use of bone-targeting radiopharmaceuticals with focus on alpha-emitters. World Journal of Radiology, 2014, 6, 480.	1.1	17
99	A fast method for rescaling voxel S values for arbitrary voxel sizes in targeted radionuclide therapy from a single Monte Carlo calculation. Medical Physics, 2013, 40, 082502.	3.0	15
100	EANM Dosimetry Committee Series on Standard Operational Procedures for Pre-Therapeutic Dosimetry II. Dosimetry prior to radioiodine therapy of benign thyroid diseases. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1126-1134.	6.4	117
101	Dosimetry of [68Ga]-labeled compounds. Applied Radiation and Isotopes, 2013, 76, 70-74.	1.5	16
102	EFOMP and EANM: joint recommendations for a curriculum for the education and training of physicists in nuclear medicine. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 645-648.	6.4	0
103	Dosimetry of 223Ra-chloride: dose to normal organs and tissues. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 207-212.	6.4	101
104	EANM perspective. Radiation Protection Dosimetry, 2013, 153, 166-169.	0.8	0
105	Curriculum for education and training of Medical Physicists in Nuclear Medicine. Physica Medica, 2013, 29, 139-162.	0.7	17
106	Treatment planning in molecular radiotherapy. Zeitschrift Fur Medizinische Physik, 2013, 23, 262-269.	1.5	44
107	Molecular radiotherapy: The NUKFIT software for calculating the time-integrated activity coefficient. Medical Physics, 2013, 40, 102504.	3.0	73
108	Is the Image Quality of I-124-PET Impaired by an Automatic Correction of Prompt Gammas?. PLoS ONE, 2013, 8, e71729.	2.5	28

#	ARTICLE	IF	CITATIONS
109	Biodistribution and Dosimetry of ¹⁷⁷ Lu-tetumab, a New Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma. Current Radiopharmaceuticals, 2013, 6, 20-27.	0.8	36
110	Monte Carlo Methods in Nuclear Medicine. Medical Radiology, 2012, , 759-768.	0.1	1
111	Combination of peptide receptor radionuclide therapy with fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma. Radiation Oncology, 2012, 7, 99.	2.7	71
112	Radiation dosimetry is a necessary ingredient for a perfectly mixed molecular radiotherapy cocktail. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 548-549.	6.4	6
113	Radioiodine for remnant ablation and therapy of metastatic disease. Nature Reviews Endocrinology, 2011, 7, 589-595.	9.6	56
114	¹³¹ I therapy in patients with benign thyroid disease does not conclusively lead to a higher risk of subsequent malignancies. Nuklearmedizin - NuclearMedicine, 2011, 50, 93-99.	0.7	20
115	Dosimetry prior to I- ¹³¹ -therapy of benign thyroid disease. Zeitschrift Fur Medizinische Physik, 2011, 21, 250-257.	1.5	26
116	Nuclear medicine dosimetry: Quantitative imaging and dose calculations. Zeitschrift Fur Medizinische Physik, 2011, 21, 246-247.	1.5	19
117	EANM Dosimetry Committee guidance document: good practice of clinical dosimetry reporting. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 192-200.	6.4	156
118	The absorbed dose to the blood is a better predictor of ablation success than the administered ¹³¹ I activity in thyroid cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 673-680.	6.4	44
119	Biokinetics and dosimetry of commonly used radiopharmaceuticals in diagnostic nuclear medicine – a review. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 2269-2281.	6.4	58
120	Facing the Nuclear Threat: Thyroid Blocking Revisited. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 3511-3516.	3.6	31
121	Radio-iodine treatment of hyperthyroidism. , 2011, , 481-484.		0
122	Dosimetry-guided high-activity ¹³¹ I therapy in patients with advanced differentiated thyroid carcinoma: initial experience. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 896-903.	6.4	72
123	EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1238-1250.	6.4	217
124	EANM procedure guidelines for therapy of benign thyroid disease. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 2218-2228.	6.4	174
125	Dosimetry is Alive and Well. Cancer Biotherapy and Radiopharmaceuticals, 2010, 25, 593-595.	1.0	4
126	In Vivo Formation of ¹³ H2AX and 53BP1 DNA Repair Foci in Blood Cells After Radioiodine Therapy of Differentiated Thyroid Cancer. Journal of Nuclear Medicine, 2010, 51, 1318-1325.	5.0	117

#	ARTICLE	IF	CITATIONS
127	Dosimetry and thyroid cancer: the individual dosage of radioiodine. <i>Endocrine-Related Cancer</i> , 2010, 17, R161-R172.	3.1	103
128	Follow-Up of Low-Risk Differentiated Thyroid Cancer Patients Who Underwent Radioiodine Ablation of Postsurgical Thyroid Remnants after Either Recombinant Human Thyrotropin or Thyroid Hormone Withdrawal. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 4171-4179.	3.6	78
129	Why radioiodine remnant ablation is right for most patients with differentiated thyroid carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 343-346.	6.4	35
130	Joint practice guidelines for radionuclide lymphoscintigraphy for sentinel node localization in oral/oropharyngeal squamous cell carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 1915-1936.	6.4	66
131	Joint Practice Guidelines for Radionuclide Lymphoscintigraphy for Sentinel Node Localization in Oral/Oropharyngeal Squamous Cell Carcinoma. <i>Annals of Surgical Oncology</i> , 2009, 16, 3190-3210.	1.5	108
132	Blood dosimetry from a single measurement of the whole body radioiodine retention in patients with differentiated thyroid carcinoma. <i>Endocrine-Related Cancer</i> , 2009, 16, 1283-1289.	3.1	70
133	The new EANM paediatric dosage card. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 1748-1748.	6.4	38
134	EANM procedure guidelines for ¹³¹ I-meta-iodobenzylguanidine (¹³¹ I-mIBG) therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 1039-1047.	6.4	212
135	EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 1405-1412.	6.4	204
136	The new EANM paediatric dosage card: additional notes with respect to F-18. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 1666-1668.	6.4	76
137	Guidelines for radioiodine therapy of differentiated thyroid cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 1941-1959.	6.4	593
138	The new EANM paediatric dosage card. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 796-798.	6.4	160
139	EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with ⁹⁰ Y-radiolabelled ibritumomab tiuxetan (Zevalin). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 616-622.	6.4	74
140	Clinical radionuclide therapy dosimetry: the quest for the "Holy Grail". <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 1699-1700.	6.4	39
141	Sentinel node in breast cancer procedural guidelines. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 2154-2159.	6.4	114
142	Spatial dose mapping for individualizing radioiodine treatment. <i>Journal of Nuclear Medicine</i> , 2007, 48, 2-4.	5.0	200
143	Radioiodine Ablation of Thyroid Remnants after Preparation with Recombinant Human Thyrotropin in Differentiated Thyroid Carcinoma: Results of an International, Randomized, Controlled Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 926-932.	3.6	405
144	A Novel Thyroid Phantom for Ultrasound Volumetry: Determination of Intraobserver and Interobserver Variability. <i>Thyroid</i> , 2006, 16, 41-46.	4.5	21

#	ARTICLE	IF	CITATIONS
145	Quantitative imaging for clinical dosimetry. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2006, 569, 467-471.	1.6	8
146	The Impact of PET and SPECT on Dosimetry for Targeted Radionuclide Therapy. Zeitschrift Fur Medizinische Physik, 2006, 16, 47-59.	1.5	107
147	Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. Journal of Nuclear Medicine, 2006, 47, 648-54.	5.0	209
148	A perspective on post-Chernobyl radioablation in young females. Journal of Nuclear Medicine, 2006, 47, 1563-4.	5.0	3
149	EANM/ESC procedural guidelines for myocardial perfusion imaging in nuclear cardiology. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 855-897.	6.4	467
150	rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. Endocrine-Related Cancer, 2005, 12, 49-64.	3.1	154
151	Introduction; 1st International Symposium on Radionuclide Therapy and Radiopharmaceutical Dosimetry. Cancer Biotherapy and Radiopharmaceuticals, 2005, 20, 45-46.	1.0	4
152	Blood dosimetry and dose-rate effects after radioiodine therapy of differentiated thyroid cancer. Journal of Nuclear Medicine, 2005, 46, 899.	5.0	12
153	Blood and bone marrow dosimetry in radioiodine therapy of differentiated thyroid cancer after stimulation with rhTSH. Journal of Nuclear Medicine, 2005, 46, 900-1; author reply 901.	5.0	7
154	Impact of ¹³¹ I diagnostic activities on the biokinetics of thyroid remnants. Journal of Nuclear Medicine, 2004, 45, 619-25.	5.0	63
155	Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 1371-1377.	6.4	95
156	Therapy of ankylosing spondylitis with ²²⁴ Ra-radium chloride: dosimetry and risk considerations. Radiation and Environmental Biophysics, 2002, 41, 173-178.	1.4	33
157	Track Structures and Dose Distributions from Decays of ¹³¹ I and ¹²⁵ I in and around Water Spheres Simulating Micrometastases of Differentiated Thyroid Cancer. Radiation Research, 2001, 156, 419-429.	1.5	25
158	The Use of Three-Dimensional Ultrasound for Thyroid Volumetry. Thyroid, 2001, 11, 569-574.	4.5	68
159	Use of Recombinant Human Thyrotropin before Radioiodine Therapy in Patients with Advanced Differentiated Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 3640-3645.	3.6	38
160	Radioiodine (¹³¹ I) treatment of hyperthyroidism: radiation protection and quality assurance. European Journal of Nuclear Medicine and Molecular Imaging, 1999, 26, 683-685.	6.4	21
161	The impact of ¹⁷⁷ Lu-octreotide therapy on ^{99m} Tc-MAG3 clearance is not predictive for late nephropathy. Oncotarget, 0, 7, 41233-41241.	1.8	16